Osmohale (Mannitol)

• Mannitol is used as an excipient in inhalation formulations to support airway clearance.
• Bronchial obstruction: enhances mucociliary clearance in obstructive airway diseases.
• Cystic fibrosis: facilitates removal of thick mucus from the lungs.
• Chronic obstructive pulmonary disease (COPD): aids airway hydration and mucus clearance.

• Mannitol acts as an osmotic agent when inhaled, establishing a gradient that draws water from the airway epithelium into the lumen. The increased airway surface liquid reduces mucus viscosity, improves ciliary function, and promotes the clearance of secretions, thereby supporting respiratory hygiene in various pulmonary conditions.

Mannitol may cause a range of respiratory and systemic reactions.

Common Side Effects

• Cough: transient irritation leading to coughing.
• Throat irritation: mild discomfort in the throat.
• Bronchospasm: temporary narrowing of the airways.
• Wheezing: audible breath sounds during exhalation.
• Headache: mild to moderate head pain.
• Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

• Severe bronchospasm: pronounced airway constriction requiring medical attention.
• Anaphylaxis: rare systemic allergic reaction.
• Pulmonary edema: accumulation of fluid in the lungs.
• Hemoptysis: coughing up blood.
• Severe allergic reaction: rash, swelling, or difficulty breathing.

• When using inhaled mannitol, consider the following precautions.
• Assess airway reactivity: perform bronchial provocation testing before initiating therapy.
• Monitor lung function: check spirometry after the first doses.
• Avoid in uncontrolled asthma: increased risk of bronchospasm.
• Use with caution in hypersensitivity: discontinue if allergic signs appear.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at ambient temperature: keep in original container, protect from moisture and heat.

Mannitol may interact with other agents affecting the respiratory system.

Major Interactions (Avoid)

• Concurrent inhaled osmotic agents: may exacerbate airway irritation.
• Beta‑agonists: may mask bronchospasm symptoms, delaying recognition.

Moderate Interactions (Monitor Closely)

• Anticholinergics: could alter airway secretions.
• Systemic diuretics: potential additive osmotic effects.
• Other excipients with irritant potential: monitor for increased cough or throat discomfort.